(Q37350194)

19 August 2017

1 reference

title

What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? (English)

1 reference

19 August 2017

Michaela J Higgins

1

1 reference

19 August 2017

Nancy E Davidson

series ordinal

2

1 reference

19 August 2017

publication date

1 January 2009

1 reference

19 August 2017

published in

Current Oncology Reports

1 reference

19 August 2017

volume

11

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

45-50

1 reference

Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review

19 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-009-0008-4

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-009-0008-4

Menopause after breast cancer: a survey on breast cancer survivors

21 January 2018

1 reference

12 December 2020

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

1 reference

12 December 2020

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

12 December 2020

Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast canc

1 reference

12 December 2020

Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).

1 reference

12 December 2020

Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

1 reference

12 December 2020

Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review

1 reference

12 December 2020

Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized Study

1 reference

12 December 2020

Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study

1 reference

12 December 2020

Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

1 reference

12 December 2020

Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life.

1 reference

12 December 2020

Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status

1 reference

12 December 2020

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

1 reference

12 December 2020

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer

1 reference

12 December 2020

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

1 reference

12 December 2020

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

1 reference

12 December 2020

Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

1 reference

12 December 2020

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

1 reference

12 December 2020

Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

1 reference

12 December 2020

Aromatase inhibitors in breast cancer

1 reference

12 December 2020

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

12 December 2020

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

12 December 2020

Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.

1 reference

12 December 2020

10.1007/S11912-009-0008-4

Identifiers

DOI

1 reference

19 August 2017

1 reference